Infectious Diseases (all articles)
Another study shows a single dose of an mRNA vaccine has maximal effects in those with past infection.
24 Jun, 2021 | 10:38h | UTCPrimary, Recall, and Decay Kinetics of SARS-CoV-2 Vaccine Antibody Responses – ACS Nano
Related: France recommends single dose of vaccine if previous Covid infection detected. AND [Preprint] More data showing a single-dose SARS-CoV-2 mRNA vaccine may be enough in individuals with previous COVID-19. AND Another study shows a single dose of mRNA vaccine may be enough for patients with previous Covid-19
Commentary on Twitter
Prior covid? Unless it's a severe case, one-dose mRNA vaccine adds considerable protection and nothing added by 2nd dose. This is now concordant w/ >20 studieshttps://t.co/8Qpuw193zk @acsnano pic.twitter.com/TJNbl8HPy9
— Eric Topol (@EricTopol) June 23, 2021
Effect of Vaccination on Household Transmission of SARS-CoV-2 in England – “the likelihood of household transmission was approximately 40 to 50% lower in households of index patients who had been vaccinated 21 days or more before testing positive than in households of unvaccinated index patients”.
24 Jun, 2021 | 09:52h | UTCRelated: Study in England showed one dose of COVID-19 vaccine can cut household transmission by up to half – This protection is on top of the reduced risk of a vaccinated person developing symptomatic infection, which is around 60 to 65% after the first dose AND Covid-19 vaccination prevents transmission from vaccinated to unvaccinated household members.
Report: SARS-CoV-2 variants and vaccines.
24 Jun, 2021 | 10:33h | UTCSARS-CoV-2 Variants and Vaccines – New England Journal of Medicine
Perspective | Delta variant triggers dangerous new phase in the pandemic.
24 Jun, 2021 | 10:43h | UTCDelta variant triggers dangerous new phase in the pandemic – Science
Analysis | Future of covid-19 vaccine pricing: lessons from influenza – “Routine use of covid-19 vaccines could strain health budgets if pricing follows the pattern seen with influenza vaccines”.
24 Jun, 2021 | 09:50h | UTCFuture of covid-19 vaccine pricing: lessons from influenza – The BMJ
Commentary on Twitter
In case you're assuming the price of Covid vaxes is going to go down, this group is here with bad news from the trajectory of flu vaxes: the more there are, the higher the prices go. Just great. ? From @jasonlschwartz & co https://t.co/66QHwazmES
— Hilda Bastian, PhD (@hildabast) June 22, 2021
CDC: mRNA vaccines are likely linked to cases of myocarditis and pericarditis – 1,226 cases of myocarditis or pericarditis have been reported mostly in people under 30.
24 Jun, 2021 | 09:51h | UTCSee also: Experts: mRNA COVID-19 vaccines likely tied to heart inflammation – CIDRAP
Related: Case series: 7 cases of myocarditis following mRNA-based COVID-19 vaccination. AND Case series: clinical and cardiac magnetic resonance imaging findings of 4 cases of myocarditis following mRNA-based COVID-19 vaccination. AND Case series: symptomatic acute myocarditis in 7 adolescents following mRNA COVID-19 vaccination. AND CDC says heart inflammation cases were higher than expected in 16- to 24-year-olds after second Covid vaccine shot, but still rare. AND Israel reports link between rare cases of heart inflammation and COVID-19 vaccination in young men. AND CDC is investigating several reports that teenagers and young adults may have developed myocarditis after receiving mRNA vaccines. Most cases were mild, more often in males than females, more often following dose 2 than dose 1, and typically, within 4 days after vaccination.
Review | My Treatment Approach to Clostridioides difficile Infection.
24 Jun, 2021 | 09:47h | UTCMy Treatment Approach to Clostridioides difficile Infection – Mayo Clinic Proceedings
[News release – not published yet] COVID-19 outpatient thrombosis prevention trial ends early – “Results suggest that not treating certain symptomatic but stable outpatients with anticoagulant or antiplatelet therapy may be the best course of action”.
23 Jun, 2021 | 10:32h | UTCCommentary: Antithrombotics No Help for Stable COVID-19 Outpatients: ACTIV-4b – TCTMD
Interactive Infographic | Interpreting a lateral flow SARS-CoV-2 antigen test – “This calculator demonstrates how interpreting a covid-19 lateral flow device (LFD) result varies according to the pre-test probability, and the sensitivity and specificity of the LFD used”.
23 Jun, 2021 | 10:29h | UTCInterpreting a lateral flow SARS-CoV-2 antigen test – The BMJ
Laboratory testing for suspected COVID-19 vaccine–induced (immune) thrombotic thrombocytopenia.
23 Jun, 2021 | 10:25h | UTC
Delta coronavirus variant: scientists brace for impact.
23 Jun, 2021 | 10:27h | UTCDelta coronavirus variant: scientists brace for impact – Nature
New Analysis reveals link between birthdays and COVID-19 spread during the height of the pandemic.
23 Jun, 2021 | 10:22h | UTCNews release: New Analysis reveals link between birthdays and COVID-19 spread during the height of the pandemic – Harvard Medical School
Original Study: Assessing the Association Between Social Gatherings and COVID-19 Risk Using Birthdays – JAMA Internal Medicine
Commentary on Twitter (thread – click for more)
The link between birthdays and Covid-19
Thread on our new study (w/ @CM_Whaley, Jon Cantor, Megan Pera) in @JAMAInternalMed
Using data on ~3M households, households in which a member had bday 2 wks prior were ~30% more likely to have a covid diagnosishttps://t.co/KHCvGAlvox
— Anupam Jena (@AnupamBJena) June 21, 2021
The Risk of Allergic Reaction to SARS-CoV-2 Vaccines and Recommended Evaluation and Management: A Systematic Review, Meta-analysis, GRADE Assessment, and International Consensus Approach.
23 Jun, 2021 | 10:23h | UTC
[Preprint] Rapid displacement of SARS-CoV-2 variant B.1.1.7 (Alpha) by B.1.617.2 (Delta) and P.1 (Gamma) in the United States.
22 Jun, 2021 | 10:12h | UTCRapid displacement of SARS-CoV-2 variant B.1.1.7 by B.1.617.2 and P.1 in the United States – medRxiv
Commentary on Twitter
???Preprint
?B.1.617.2 Delta and P.1 are growing faster than B.1.1.7 & B.1.617.2 is growing faster than P.1 in the US
?B.1.617.2 will soon be the dominant variant in the US
?B.1.617.2 is growing more rapidly in counties with lower vaccination rateshttps://t.co/6Rf3p5N4ed pic.twitter.com/sVzyQRXn12— Antibiotic Steward ???Bassam Ghanem (@ABsteward) June 22, 2021
Ivermectin is the new hydroxychloroquine, take 2 – “Ivermectin shouldn’t be used to treat COVID-19 outside of the context of a well-designed clinical trial”.
22 Jun, 2021 | 10:08h | UTCIvermectin is the new hydroxychloroquine, take 2 – Science-Based Medicine
Related: [Preprint] Meta-analysis of RCT: Ivermectin for the treatment of COVID-19 – no effect on all-cause mortality, length of stay, or viral clearance AND M-A: Prophylaxis against Covid-19: 1 – no benefit from Hydroxychloroquine; 2 – as studies on ivermectin so far have been small, it remains very uncertain whether ivermectin reduces SARS-CoV-2 infection AND Therapeutics and COVID-19 | WHO guideline update advises Ivermectin should only be used to treat COVID-19 within clinical trials AND EMA advises against use of ivermectin for the prevention or treatment of COVID-19 outside randomized clinical trials AND FDA: Why you should not use Ivermectin to treat or prevent COVID-19 AND RCT: Ivermectin does not improve time to resolution of symptoms among adults with mild COVID-19 AND NIH Guideline Statement: “there are insufficient data to recommend either for or against the use of ivermectin for the treatment of COVID-19” AND Video (5min): Ivermectin for COVID-19 | A Doctor Explains
Perspective | COVID-19: The rise and rise of Delta.
22 Jun, 2021 | 10:10h | UTCCOVID-19: The rise and rise of Delta – Sciblogs
Case report: Multisystem inflammatory syndrome in an adult after SARS-CoV-2 infection.
22 Jun, 2021 | 10:04h | UTC
Increased transmissibility and global spread of SARS-CoV-2 variants of concern – “Estimated transmissibility increases of alpha 29% (95% CI: 24–33), beta 25% (95% CI: 20–30), gamma 38% (95% CI: 29–48) & delta 97% (95% CI: 76–117)”.
21 Jun, 2021 | 08:55h | UTC
Commentary on Twitter
NEW publication in Eurosurveillance
Increased transmissibility & global spread of #SARSCoV2 VOC & VOI
Estimated transmissibility increases of alpha 29% (95% CI: 24–33), beta 25% (95% CI: 20–30), gamma 38% (95% CI: 29–48) & delta 97% (95% CI: 76–117)
⬇️https://t.co/pmyfQMM78y pic.twitter.com/Xz3cOImRvc
— Maria Van Kerkhove (@mvankerkhove) June 17, 2021
National surveillance in England showed low risk of reinfection with Covid-19 – “There were 15,893 possible reinfections with SARS-CoV-2 identified up to 30 May 2021 in England throughout the pandemic, out of nearly 4 million people with confirmed infections. This is equivalent to around 0.4% cases becoming reinfected”.
21 Jun, 2021 | 08:56h | UTCNew national surveillance of possible COVID-19 reinfection, published by PHE – Public Health England
Related: Had COVID? You’ll probably make antibodies for a lifetime – Nature AND COVID-19 reinfection rate less than 1 percent for those with severe illness, study finds. AND Study shows low risk of SARS-CoV-2 reinfection 1 year after primary infection.
WHO says delta is becoming the dominant Covid variant globally.
21 Jun, 2021 | 08:54h | UTCWHO says delta is becoming the dominant Covid variant globally – CNBC
Perspective | A beautiful idea: how COVAX has fallen short.
21 Jun, 2021 | 08:52h | UTCA beautiful idea: how COVAX has fallen short – The Lancet
Commentaries on Twitter
#COVAX was meant to supply #COVID19 vaccines for all based on solidarity and equity. Instead, it relies on rich countries' willingness to share their doses—Ann Danaiya Usher tracks the ambitions and shortcomings of COVAX: https://t.co/FbAZ1D8M4j #VaccinEquity pic.twitter.com/q880pzeU1s
— The Lancet (@TheLancet) June 19, 2021
#Vaccine doses given/100 inhabitants…?Rich countries praising solidarity by contributing to #COVAX while making sure that there is barely any #COVID19 vaccine left to be purchased through covax.
Check also @newhumanitarian: https://t.co/K1zzM6O3on pic.twitter.com/IpH0mDJqwC
— Tim Buder (@Tim_Buder) February 10, 2021
“COVAX has delivered over 72m doses to 125 countries. But that is far less than 172m it should have delivered by now. Of the 2.1 billion COVID-19 vaccine doses administered worldwide so far, COVAX has been responsible for less than 4%"#PeoplesVaccinehttps://t.co/TZKc8YPAdJ
— Steve Jackson (@stevejacksonHN) June 20, 2021
M-A: Azithromycin does not reduce the need for invasive mechanical ventilation or mortality in patients with Covid-19.
21 Jun, 2021 | 08:45h | UTC
Study: Sperm parameters not changed before and after COVID-19 mRNA vaccination.
21 Jun, 2021 | 08:50h | UTCSperm Parameters Before and After COVID-19 mRNA Vaccination – JAMA
Concerned about the latest AstraZeneca news? These 3 graphics help you make sense of the risk – “Two people in Australia have died from thrombosis with thrombocytopenia after 3.8 million doses of the AstraZeneca vaccine delivered”.
21 Jun, 2021 | 08:48h | UTC
Perspective | Sewage sleuths helped an Arizona town beat back Covid-19. For wastewater epidemiology, that’s just the start.
21 Jun, 2021 | 08:43h | UTCRelated: The myriad ways sewage surveillance is helping fight COVID around the world – Nature AND Testing sewage can give school districts, campuses and businesses a heads-up on the spread of COVID-19 – The Conversation AND It’s time to begin a national wastewater testing program for Covid-19 – STAT AND Coronavirus: Testing sewage an ‘easy win’ – BBC